|
Post by hophead on Nov 20, 2014 20:44:20 GMT
Yeah tunis. Reminds me of another POS stem cell stock dabbling in the amd space.
|
|
|
Post by jckrdu on Nov 20, 2014 20:49:13 GMT
Thanks for the thoughts tradeup and jck. I think I will hold unless this thing breaks $1.20 for now. Hopefully as jim noted there is a delayed reaction to this stock and we see some buying tomorrow and into next week. Not that surprising to see the traders that got in for a quick move higher sell today, as the immediate move up did not happen. I bought in at an average of $1.15. Will hold to see how it trades after the initial dumping. I still think some institutions could start taking positions over the next few weeks.
|
|
|
Post by hophead on Nov 20, 2014 20:51:55 GMT
I honestly don't see why companies do these conference calls. PPS always tanks immediately after. I'm averaged in around $1.18. Going to see what comes tomorrow. Can this junk really go that much lower?
|
|
|
Post by CM kipper007 on Nov 20, 2014 22:11:48 GMT
I think the only thing that will make a difference here is if there is a quick result from the court case.
Any idea when that is due to be resolved?
|
|
|
Post by jckrdu on Nov 20, 2014 22:45:39 GMT
I honestly don't see why companies do these conference calls. PPS always tanks immediately after. I'm averaged in around $1.18. Going to see what comes tomorrow. Can this junk really go that much lower? Sure, it can go lower. The purpose of today's dog and pony show was to get institutional investors interested in taking a long term position in the stock. Judging by the Q&A, they had a number of institutional analysts in the room. I think they delivered a pretty good message today; solid results in spinal and AMD trials, and news of Phase 2 starting in spinal this year, and AMD 1st QTR next year. Will the institutions start adding? I'm not sure... I'm going to give it a couple of weeks. I don't think any institutional investors dumped today as the news was generally positive on their 2 main programs. (They did announce that their Alzhimer's trial is not going to move forward because they didn't see an efficacy signal, so perhaps some are focusing on that.) I think traders dumped today, which is why I'm inclined to give it a little more time.
|
|
|
Post by dayanand33 on Nov 21, 2014 2:44:49 GMT
I honestly don't see why companies do these conference calls. PPS always tanks immediately after. I'm averaged in around $1.18. Going to see what comes tomorrow. Can this junk really go that much lower? Sure, it can go lower. The purpose of today's dog and pony show was to get institutional investors interested in taking a long term position in the stock. Judging by the Q&A, they had a number of institutional analysts in the room. I think they delivered a pretty good message today; solid results in spinal and AMD trials, and news of Phase 2 starting in spinal this year, and AMD 1st QTR next year. Will the institutions start adding? I'm not sure... I'm going to give it a couple of weeks. I don't think any institutional investors dumped today as the news was generally positive on their 2 main programs. (They did announce that their Alzhimer's trial is not going to move forward because they didn't see an efficacy signal, so perhaps some are focusing on that.) I think traders dumped today, which is why I'm inclined to give it a little more time. But why hold this stock now when there is no near term news. Lack of news could tank this further, isn't it?
|
|
|
Post by JHam on Nov 21, 2014 3:29:47 GMT
Surprised that there wasn't much of a pop on this. I have read bits and pieces of the presentation, and while the Alzheimers data doesn't sound too encouraging, what they had to say about AMD sounded pretty impressive. It may take some time for it all to marinate with the market, but I don't see why it wouldn't go up from these levels. Good luck to those holding.
|
|
|
Post by jckrdu on Nov 21, 2014 14:48:40 GMT
Sure, it can go lower. The purpose of today's dog and pony show was to get institutional investors interested in taking a long term position in the stock. Judging by the Q&A, they had a number of institutional analysts in the room. I think they delivered a pretty good message today; solid results in spinal and AMD trials, and news of Phase 2 starting in spinal this year, and AMD 1st QTR next year. Will the institutions start adding? I'm not sure... I'm going to give it a couple of weeks. I don't think any institutional investors dumped today as the news was generally positive on their 2 main programs. (They did announce that their Alzhimer's trial is not going to move forward because they didn't see an efficacy signal, so perhaps some are focusing on that.) I think traders dumped today, which is why I'm inclined to give it a little more time. But why hold this stock now when there is no near term news. Lack of news could tank this further, isn't it? Hey Day - There's certainly a short-term risk to continue to hold. But - per my prior posts - my belief is that the news STEM released yesterday was generally very good. IMO, at least 1 of the many institutional analysts that attended yesterday's update will be issuing "buy" ratings with a higher pps target on the stock sometime in the next 1-2 weeks. In the interim, the traders that were expecting an immediate pop are taking some off the table. I've decided to assume that short-term risk, as I think there's a good probability for upgrades and some institutional buying starting over the next few weeks. While it can ceratinly move lower, current prices of $1.20ish are near the 52 week low, so even if it does retrace in the near-term on trader selling pressure, I'm not sure how much it would fall given the good news released yesterday. If it moves below my average cost basis of $1.15 on heavy volume, that's when I'll consider selling. For now, I'm looking to get past the near-term (and IMO temporary) trader selling pressure, and hold for upgrades over the next 1-2 weeks where buying pressure has a decent probability of increasing.
|
|
|
Post by jckrdu on Nov 21, 2014 14:53:11 GMT
But why hold this stock now when there is no near term news. Lack of news could tank this further, isn't it? Hey Day - There's certainly a short-term risk to continue to hold. But - per my prior posts - my belief is that the news STEM released yesterday was generally very good. IMO, at least 1 of the many institutional analysts that attended yesterday's update will be issuing "buy" ratings with a higher pps target on the stock sometime in the next 1-2 weeks. In the interim, the traders that were expecting an immediate pop are taking some off the table. I've decided to assume that short-term risk, as I think there's a good probability for upgrades and some institutional buying starting over the next few weeks. While it can ceratinly move lower, current prices of $1.20ish are near the 52 week low, so even if it does retrace in the near-term on trader selling pressure, I'm not sure how much it would fall given the good news released yesterday. If it moves below my average cost basis of $1.15 on heavy volume, that's when I'll consider selling. For now, I'm looking to get past the near-term (and IMO temporary) trader selling pressure, and hold for upgrades over the next 1-2 weeks where buying pressure has a decent probability of increasing. Also note that a considerable amount of the buying that occurred over the past 2 weeks in anticipation of yesterday's event, was done at a pps over $1.20... so a good percentage of traders that sell below that will be selling at a loss. That fact should help mitigate selling pressure below $1.20, IMO... but we'll see. I'll be watching the volume closely.
|
|
|
Post by jckrdu on Nov 24, 2014 20:50:27 GMT
Sold 25% for a tiny gain (essentially broke even) and moved into ONCS for Dec 3/4 Phase 2 Melonoma results.
|
|
|
Post by jckrdu on Nov 25, 2014 15:46:55 GMT
Sold 25% for a tiny gain (essentially broke even) and moved into ONCS for Dec 3/4 Phase 2 Melonoma results. Sold the rest of my STEM this morning (broke even to a small loss) and moved it into ONCS.
|
|
|
Post by CM kipper007 on Nov 25, 2014 15:53:26 GMT
Do you think people are holing out until the court case is over? That could still take some time.
|
|
|
Post by jckrdu on Nov 25, 2014 16:54:41 GMT
Do you think people are holing out until the court case is over? That could still take some time. I don't think the court case is keeping anyone away, as the preliminary discovery favors STEM IMO. A lot of folks/traders got in for the "Investor Day" event, and while IMO the news was good, it wasn't good enough to bring in heavy new demand... so the traders all sold after it didn't pop higher. This could still trend higher over time IMO, but I saw some near-term opportunities elsewhere, so decided to exit whith a small loss. (Footnote on the "small loss": Moving out of OCAT on The Lancet and into STEM helped me avoid a 20% move lower on OCAT, so that preservation of capital was still worth the move, even though I did lose money on the STEM trade itself.)
|
|
|
Post by dayanand33 on Nov 25, 2014 16:55:11 GMT
Sold 25% for a tiny gain (essentially broke even) and moved into ONCS for Dec 3/4 Phase 2 Melonoma results. Sold the rest of my STEM this morning (broke even to a small loss) and moved it into ONCS. ONCS is soaring today. Nice move! Congrats.
|
|
|
Post by tunis on Dec 11, 2014 15:57:24 GMT
So is STEM heading under $1
|
|
|
Post by CM kipper007 on Dec 11, 2014 16:13:07 GMT
So is STEM heading under $1 Might change if they can get royalties from CUR. Not looking good right now though.
|
|
|
Post by dayanand33 on Dec 12, 2014 15:13:35 GMT
So is STEM heading under $1 Might change if they can get royalties from CUR. Not looking good right now though. Usually such court battles are long drawn. I see very little chances of any type of settlement so soon.
|
|
|
Post by CM kipper007 on Dec 12, 2014 15:35:58 GMT
Under a Now.
|
|
|
Post by Jimmywho on Dec 18, 2014 14:31:10 GMT
StemCells, Inc. Transplants First Participant in Phase II Clinical Trial in Cervical Spinal Cord Injury
12/18/2014 | 08:00 AM ET | GlobeNewswire
NEWARK, Calif., Dec. 18, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, announced today that it has transplanted the first subject in its Phase II Pathway® Study assessing the efficacy of its proprietary HuCNS-SC® (purified human neural stem cells) platform technology for the treatment of cervical spinal cord injury (SCI). The transplant was performed at the University of Miami Hospital within the Miller School of Medicine, home to The Miami Project to Cure Paralysis, one of the world's most comprehensive spinal cord injury research centers dedicated to finding effective treatments for paralysis.
|
|
|
Post by CM kipper007 on Dec 22, 2014 21:27:39 GMT
I see that STEM released a couple of PRs since they went sub $, and would like to know what others see happening with the company in the next2-3 months.
Is this a buying opportunity?
Were the PRs in reaction to the share price slipping and trying to get out of that de-listing zone? Will there be more to come?
|
|